| 1. |
|
|
| 2. |
- Bergström, Stig M., et al.
(författare)
-
Local and trans-Atlantic chemostratigraphic significance of new δ13Ccarb data from the Sandbian and Katian Stages (Middle–Upper Ordovician) of the Oslo region, Norway
- 2017
-
Ingår i: GFF. - : Informa UK Limited. - 1103-5897 .- 2000-0863. ; 139:4, s. 289-300
-
Tidskriftsartikel (refereegranskat)abstract
- Late Sandbian to early Katian δ13Ccarb chemostratigraphy has in Norway been described in only two previous reports that dealt with two geographically rather widely separated areas, namely the Oslo-Asker district and the Nes-Hamar district. No data have been available from the Ordovician outcrop areas between these districts that could help clarify the partly unclear regional stratigraphic relations across the Oslo region. A chemostratigraphic study of the classical road section at Tønnerud in the northwestern Hadeland district about halfway between the previously investigated districts resulted in the recognition of two δ13C excursions, namely one in the uppermost Furuberget Formation tentatively identified as the Guttenberg Isotopic Carbon Excursion and one in the lower Solvang Formation that is classified as the KOPE (RAKVERE) excursion. Based on these results, the Furuberget and Solvang formations are interpreted to be separated by a significant gap in the study area corresponding to the Oandu and lower Rakvere regional Baltoscandic stages. This suggests that the Tønnerud succession is less complete stratigraphically than those in the Oslo-Asker district. Similar gaps are not uncommon in this interval in Baltoscandia and in North America and probably reflect both eustatic and local epeirogenetic movements that make it difficult to establish a regionally applicable sequence stratigraphy.
|
|
| 3. |
- Bruton, M, et al.
(författare)
-
Expression of High Mobility Group Protein B1 in Cardiac Tissue of Elderly Patients with Coronary Artery Disease with or without Inflammatory Rheumatic Disease
- 2017
-
Ingår i: Gerontology. - : S. Karger AG. - 1423-0003 .- 0304-324X. ; 63:4, s. 337-349
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> It is known from clinical practice and observational studies that elderly patients with a diagnosis of inflammatory rheumatic diseases (IRD) bear a significantly increased risk for cardiovascular diseases such as coronary artery disease (CAD) and heart failure. The molecular mechanism, however, is still not known. Recently, high mobility group protein B1 (HMGB1), a ubiquitous, highly conserved single polypeptide expressed in all mammal eukaryotic cells, has been identified to mediate myocardial dysfunction in vitro once released from the nuclei of cardiomyocytes. <b><i>Objective:</i></b> To investigate whether HMGB1 and its receptors are expressed in cardiac muscles of elderly patients with CAD with or without IRD. <b><i>Methods:</i></b> HMGB1 and its 3 well-known receptors, receptor for advanced glycation end products, Toll-like receptor 2 (TLR2), and TLR4, were examined by immunohistochemistry on myocardial biopsy specimens from 18 elderly patients with CAD (10 with IRD, 8 without IRD). Furthermore, total HMGB1 protein levels were measured by Western blot from the cardiac biopsies in 5 patients with and 5 without IRD. <b><i>Results:</i></b> Pathologic cytosolic HMGB1 in cardiomyocytes was massively recorded in all patients with IRD, but only slightly expressed in 1 patient without IRD. Total HMGB1 levels were also consistently lower in myocardial muscle biopsies of patients with IRD compared to those without IRD. Furthermore, all 3 HMGB1 receptors were expressed in cardiomyocytes of all patients. <b><i>Conclusion:</i></b> The increased cytosolic expression of HMGB1 in cardiomyocytes and the lower total amount of HMGB1 in the cardiac specimens of IRD patients is consistent with a greater release of HMGB1 from the myocardial nuclei in IRD than non-IRD individuals. Thus, the HMGB1 signaling pathways may be more easily activated in elderly CAD patients with concomitant IRD and trigger a detrimental inflammatory process causing severe cardiovascular problems. Therefore, targeting HMGB1 in IRD patients might reduce the risk for cardiovascular events.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
